AR031766A1 - Terapia - Google Patents

Terapia

Info

Publication number
AR031766A1
AR031766A1 ARP010105452A ARP010105452A AR031766A1 AR 031766 A1 AR031766 A1 AR 031766A1 AR P010105452 A ARP010105452 A AR P010105452A AR P010105452 A ARP010105452 A AR P010105452A AR 031766 A1 AR031766 A1 AR 031766A1
Authority
AR
Argentina
Prior art keywords
therapy
dihydroxyhept
enoic
amin
methylsulfonyl
Prior art date
Application number
ARP010105452A
Other languages
English (en)
Spanish (es)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9903629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR031766(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR031766A1 publication Critical patent/AR031766A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP010105452A 2000-11-22 2001-11-22 Terapia AR031766A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0028429.9A GB0028429D0 (en) 2000-11-22 2000-11-22 Therapy

Publications (1)

Publication Number Publication Date
AR031766A1 true AR031766A1 (es) 2003-10-01

Family

ID=9903629

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010105452A AR031766A1 (es) 2000-11-22 2001-11-22 Terapia

Country Status (34)

Country Link
US (1) US6858618B2 (OSRAM)
EP (1) EP1339409B1 (OSRAM)
JP (2) JP5062940B2 (OSRAM)
KR (1) KR100815042B1 (OSRAM)
CN (1) CN1268339C (OSRAM)
AR (1) AR031766A1 (OSRAM)
AT (1) ATE394103T1 (OSRAM)
AU (2) AU2002214165B9 (OSRAM)
BG (1) BG66009B1 (OSRAM)
BR (1) BR0115511A (OSRAM)
CA (1) CA2429263C (OSRAM)
CY (1) CY1110428T1 (OSRAM)
CZ (1) CZ301583B6 (OSRAM)
DE (1) DE60133921D1 (OSRAM)
DK (1) DK1339409T3 (OSRAM)
EE (1) EE05507B1 (OSRAM)
ES (1) ES2305118T3 (OSRAM)
GB (1) GB0028429D0 (OSRAM)
HU (1) HUP0301380A3 (OSRAM)
IL (2) IL155919A0 (OSRAM)
IS (1) IS6819A (OSRAM)
MX (1) MXPA03004336A (OSRAM)
MY (1) MY134902A (OSRAM)
NO (1) NO326245B1 (OSRAM)
NZ (1) NZ525754A (OSRAM)
PL (1) PL365386A1 (OSRAM)
PT (1) PT1339409E (OSRAM)
RU (1) RU2294744C2 (OSRAM)
SI (1) SI1339409T1 (OSRAM)
SK (1) SK6212003A3 (OSRAM)
TW (1) TWI238720B (OSRAM)
UA (1) UA75614C2 (OSRAM)
WO (1) WO2002041895A1 (OSRAM)
ZA (1) ZA200303636B (OSRAM)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
US7470724B2 (en) * 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7417055B2 (en) * 2003-04-25 2008-08-26 Gilead Sciences, Inc. Kinase inhibitory phosphonate analogs
CA2523083C (en) 2003-04-25 2014-07-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
US7407965B2 (en) * 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US20090247488A1 (en) * 2003-04-25 2009-10-01 Carina Cannizzaro Anti-inflammatory phosphonate compounds
US7452901B2 (en) * 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US20050261237A1 (en) * 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
US7396927B2 (en) * 2003-08-28 2008-07-08 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
US7432273B2 (en) * 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
WO2005051921A1 (en) 2003-11-24 2005-06-09 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
PT1689723E (pt) * 2003-12-02 2011-07-06 Teva Pharma Padrão referência para a caracterização de rosuvastatina
US20070179166A1 (en) * 2003-12-24 2007-08-02 Valerie Niddam-Hildesheim Process for preparation of statins with high syn to anti ratio
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
KR20070088324A (ko) * 2004-05-26 2007-08-29 케이지케이 시너자이즈 인코포레이티드 플라보노이드 및 토코트리에놀을 포함하는 기능성 식품 및그에따른 방법
US7179916B2 (en) * 2004-07-13 2007-02-20 Teva Pharmaceutical Industries Ltd. Process for the preparation of rosuvastatin
JP2008508291A (ja) 2004-07-27 2008-03-21 ギリアード サイエンシーズ， インコーポレイテッド 抗ｈｉｖ剤としてのヌクレオシドホスホネート結合体
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
CA2594017C (en) 2005-02-22 2010-04-20 Teva Pharmaceutical Industries Ltd. Preparation of rosuvastatin
KR20070062996A (ko) * 2005-08-16 2007-06-18 테바 파마슈티컬 인더스트리즈 리미티드 결정성 로수바스타틴 중간체
US9427437B2 (en) 2008-01-31 2016-08-30 The Trustees Of The University Of Pennsylvania Hypercholesterolemia and tendinous injuries
US8383614B2 (en) * 2008-01-31 2013-02-26 The Trustees Of The University Of Pennsylvania Hypercholestrolemia and tendinous injuries
EP2298745B1 (en) 2008-05-27 2014-09-03 Changzhou Pharmaceutical Factory Preparation method of rosuvastatin calcium and its intermediates
EP2307435B1 (en) 2008-07-08 2012-06-13 Gilead Sciences, Inc. Salts of hiv inhibitor compounds
IL314360B2 (en) 2012-09-17 2025-09-01 F Hoffmann La Roche Ltd Method for the synthesis of thyroid hormone analogs and their polymorphs
US9132117B2 (en) 2013-06-17 2015-09-15 Kgk Synergize, Inc Compositions and methods for glycemic control of subjects with impaired fasting glucose
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
EP3661937B1 (en) 2017-08-01 2021-07-28 Gilead Sciences, Inc. Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) for treating viral infections
PE20220164A1 (es) 2019-05-27 2022-01-28 Immatics Us Inc Vectores viricos y uso de los mismos en terapias celulares adoptivas
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
US20220056411A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
TW202245775A (zh) * 2021-02-01 2022-12-01 美商瑪德瑞高製藥公司 用於治療肝病症或脂質病症之瑞舒伐他汀（Ｒｏｓｕｖａｓｔａｔｉｎ）和瑞司美替隆（Ｒｅｓｍｅｔｉｒｏｍ）的治療組合
US12377104B1 (en) 2024-02-06 2025-08-05 Madrigal Pharmaceuticals, Inc. Methods for treating a fatty liver disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2051907C1 (ru) * 1989-05-22 1996-01-10 Сандос АГ Способ получения 7-замещенной гептен-6-овой кислоты
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US6369103B1 (en) * 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
EP1322289B1 (en) * 2000-09-20 2007-07-25 Jagotec AG Spray drying process of compositions containing fenofibrate

Also Published As

Publication number Publication date
HK1056691A1 (en) 2004-02-27
US20040072852A1 (en) 2004-04-15
IL155919A (en) 2009-09-01
CZ301583B6 (cs) 2010-04-21
IL155919A0 (en) 2003-12-23
DE60133921D1 (de) 2008-06-19
BR0115511A (pt) 2003-12-30
NO326245B1 (no) 2008-10-27
KR20030048479A (ko) 2003-06-19
JP2010031047A (ja) 2010-02-12
NO20032292D0 (no) 2003-05-21
GB0028429D0 (en) 2001-01-10
AU2002214165B9 (en) 2013-07-04
PL365386A1 (en) 2005-01-10
HUP0301380A2 (hu) 2003-10-28
AU1416502A (en) 2002-06-03
JP5062940B2 (ja) 2012-10-31
EE200300239A (et) 2003-08-15
UA75614C2 (uk) 2006-05-15
RU2294744C2 (ru) 2007-03-10
NZ525754A (en) 2004-10-29
TWI238720B (en) 2005-09-01
HUP0301380A3 (en) 2007-03-28
CN1630520A (zh) 2005-06-22
IS6819A (is) 2003-05-19
PT1339409E (pt) 2008-07-07
JP2004522714A (ja) 2004-07-29
EP1339409B1 (en) 2008-05-07
CA2429263C (en) 2009-03-17
BG107811A (bg) 2004-03-31
MY134902A (en) 2007-12-31
ATE394103T1 (de) 2008-05-15
CY1110428T1 (el) 2015-04-29
EE05507B1 (et) 2012-02-15
US6858618B2 (en) 2005-02-22
EP1339409A1 (en) 2003-09-03
WO2002041895A1 (en) 2002-05-30
ZA200303636B (en) 2004-08-12
SI1339409T1 (sl) 2008-08-31
MXPA03004336A (es) 2003-08-19
CA2429263A1 (en) 2002-05-30
SK6212003A3 (en) 2003-11-04
CZ20031406A3 (cs) 2003-09-17
DK1339409T3 (da) 2008-09-08
NO20032292L (no) 2003-07-17
ES2305118T3 (es) 2008-11-01
CN1268339C (zh) 2006-08-09
BG66009B1 (bg) 2010-10-29
AU2002214165B2 (en) 2006-12-14
KR100815042B1 (ko) 2008-03-18

Similar Documents

Publication Publication Date Title
AR031766A1 (es) Terapia
CR6687A (es) Composiciones farmaceuticas que comprenden inhibidoras de la hmg coa reductasa
DE60140581D1 (de) Pharmazeutische Zusammensetzungen beinhaltend Kristallsalze von 7-Ä4-(4-Fluorophenyl)-6-isopropyl-2-Ämethyl(methylsulfonyl)aminoÜpyrimidin-5-ylÜ-(3R,5S)-3,5-dihydroxyhept-6-ensäure
BR0208678A (pt) Composto, composição farmacêutica, uso de um composto
ECSP034774A (es) Pirazolopirimmidinas como agentes terapeuticos
IS2820B (is) Samsettar samsetningar sem ná yfir (E)-7-[4-(4-flúorofenýl)-6-ísóprópyl-2-[metýl(metýlsúlfónýl)-amínó]pýrimídín-5-ýl](3R,5S)-3,5-díhýdroxýhept-6-enósýru
DK1377589T3 (da) Oxazolyl-pyrazolderivater som kinaseinhibitorer
IS2689B (is) Kristallað form bis [(E)-7-[4-(4-flúorfenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl) amínó]pýrimídin-5-ýl](3R, 5S)-3,5-díhýdroxýhept-6-ensýru] kalsíumsalts
CL2010000113A1 (es) Proceso para la preparacion de una composicion farmaceutica que comprende mezclar el acido (+)-7-[4-(4-fluorofenil)-6-isopropil-2-(n-metil-n-metilsulfonilamino)pirimidin-5-il(3r,5s)-dihidroxi-(e)-6-heptenoico o una sal del mismo con un vehiculo farmaceuticamente aceptable (divisional solicitud 2383-2001).
ATE359791T1 (de) Pyrimidin-2,4-dion-derivate als matrix- metalloproteinase-hemmer
NO20043115L (no) Substituerte diketopiperaziner som oksytocin antagonister
BR0017120A (pt) Composição farmacêutica
HK1040924A1 (zh) 降膽固醇劑的應用
EA200400877A1 (ru) 2'-гало-3',5'-диалкоксифен-1'-илимино-2-имидазолидиновые производные и их применение для лечения недержания мочи
BR0209956A (pt) Uso da 4- (2-fluorofenil)-6-metil-2- (1-piperazinil)tieno [2,3-d]pirimidina para o tratamento da dor
BR0208814A (pt) Uso de derivados de ariletenossulfonamida
UY27049A1 (es) Composiciones farmacéuticas
UY30336A1 (es) Composiciones farmacéuticas conteniendo ácido (e)-7-(4-(4-fluorofenil)-6-isopropil-2-(metil(metilsulfonil)amino)pirimidin-5-il)-(3r,5s)-3,5-dihidroxihept-6-enoico y sales farmacéuticamente aceptables de la misma

Legal Events

Date Code Title Description
FB Suspension of granting procedure